N@N

BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technologya"Enhanced Capabilities

^{Published on 2011-04-06 02:40:56 - Market Wire}
 

NEWTOWN, Pa.--([ BUSINESS WIRE ])--BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in April and May. BioClinica experts will discuss industry trends and also demonstrate its suite of technologies and solutions.

"Blinded Reads in Rheumatoid Arthritis Clinical Trials: Adjudication Rates for Varying Thresholds Based on Change Scores of Two Reader Utilizing X-Ray of Hand and Feet"

Global Clinical Supplies Group is a forum for open discussion to share knowledge and the industrya™s best practices for clinical supply and related professionals. BioClinica will demonstrate its expanded suite of clinical trial services that maximize efficiency and manageability of the clinical trial process.

Jennifer Price, Director, Clinical Solutions will present aThree Case Studies of Converting to CDISC (CDASH and SDTM) Standarda™ on April 14, 2011 in the Emerging Device Standard track. CDISC is a global, open, multidisciplinary, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata.

BioClinica has extensive expertise in neurology clinical trials and as a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica will demonstrate how its systems and processes ensure that the end-to-end result is as efficient and expedient as possible. BioClinica will also present two posters, entitled aAccuracy and Reproducibility Assessment of FreeSurfer and Jacobian Integration Techniquesa and aLabeling of Brain MRI Images Using Atlas Propagation and Classification-Based Nearest Neighbor Transform.a

Jonathan Andrus, MS, CQA, CCDM, and VP of Data Management and Quality will run a workshop on aData Manager and CRA Collaboration in an eClinical Environment a" Working Together for Quality Data.a This workshop will focus on aspects that clinical research professionals from both the data management and clinical monitoring arena can do together. These practices lead to improved data quality and increase the speed and quality by which study databases can be reviewed, cleaned and locked. When these roles collaborate effectively, clinical trial management teams benefit from a more productive working relationship.

Outsourcing in Clinical Trials Europe brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.

Harris Ahmad, MD, Associate Medical Director of Medical Affairs, will present a poster entitled aBlinded Reads in Rheumatoid Arthritis Clinical Trials: Adjudication Rates for Varying Thresholds Based on Change Scores of Two Reader Utilizing X-Ray of Hand and Feet,a on Friday, May 27, 2011 at 11:45 a.m. a" 1:30 p.m. The Annual European Congress of Rheumatology Congress will cover the broad spectrum of the rheumatic diseases and include state-of-the-art lectures, basic science and clinical symposia, abstract sessions, presentation and discussion of difficult cases, workshops and special interest group sessions.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit [ www.bioclinica.com ].

Certain matters discussed in this press release are aforward-looking statementsa intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995.In particular, the Companya™s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Companya™s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Companya™s control.The factors discussed herein and expressed from time to time in the Companya™s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Companya™s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.